- Home
- EDTK vs MBRX Comparison
EDTK vs MBRX Comparison
Compare EDTK & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDTK | MBRX |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3M | 12.7M |
| IPO Year | 2019 | 2016 |
Fundamental Metrics
Financial Performance| Metric | EDTK | MBRX |
|---|---|---|
| Price | $0.92 | $0.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.00 |
| AVG Volume (30 Days) | 6.9K | ★ 720.3K |
| Earning Date | 01-16-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $0.16 |
| 52 Week High | $1.18 | $7.98 |
Technical Indicators
Market Signals| Indicator | EDTK | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 47.09 |
| Support Level | N/A | $0.16 |
| Resistance Level | N/A | $2.26 |
| Average True Range (ATR) | 0.00 | 0.06 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 0.00 | 96.60 |
Price Performance
Historical ComparisonAbout EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.